Vladimir Semiglazov read more here.

Sandra M. Swain, M read more here .D.D., Sung-Bae Kim, M.D., Jungsil Ro, M.D., Vladimir Semiglazov, M.D., Mario Campone, M.D., Eva Ciruelos, M.D., Jean-Marc Ferrero, M.D., Andreas Schneeweiss, M.D., Sarah Heeson, B.Sc., Emma Clark, M.Sc., Graham Ross, F.F.P.M., Mark C. Benyunes, M.D.D. For the CLEOPATRA Study Group: Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer The overexpression of individual epidermal growth factor receptor 2 in breast cancer results in more aggressive disease with a poor prognosis.1 The humanized anti-HER2 monoclonal antibodies pertuzumab and trastuzumab are more vigorous in combination than alone because of more extensive signaling blockade.2,3 We investigated combination therapy with docetaxel for first-collection treatment of HER2-positive metastatic breast cancer in the Clinical Evaluation of Pertuzumab and Trastuzumab trial.